Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

Core Points - Cytokinetics has announced the seventh annual Communications Grant Program, offering five grants of $20,000 each to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure [1][2] - The program aims to enhance communications, awareness, and community engagement for underfunded nonprofit patient organizations [2] - Eligible organizations must be nonprofit or registered charities in the U.S., Canada, Europe, or the U.K., and serve HCM or heart failure communities [3] Grant Program Details - The deadline for applications is November 4, 2024, with recipients announced in January 2025 [1][3] - The grants can support various initiatives, including programming or personnel, to help organizations implement crucial communications and outreach activities [2][3] - Previous grant recipients include ALS Therapy Development Institute, Cardiomyopathy UK, Global Heart Hub, HeartBrothers Foundation, and WomenHeart [2] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular treatments, focusing on muscle biology and cardiac muscle performance [4] - The company is preparing for regulatory submissions for aficamten, a cardiac myosin inhibitor, following positive Phase 3 trial results [4] - Cytokinetics is also developing other drug candidates, including omecamtiv mecarbil for heart failure and CK-586 for HFpEF [4]